Contineum Therapeutics, Inc. Class A Common Stock Capital Reinvestment Ratio
Contineum Therapeutics, Inc. Class A Common Stock capital reinvestment ratio. Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Capital Reinvestment Ratio of 0.00x as of June 2023, meaning it reinvests 0% of its operating cash flow ($40.67 Million) in capital expenditures ($31.00K). Check CTNM cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Contineum Therapeutics, Inc. Class A Common Stock (2023–2023)
Capital reinvestment ratio of Contineum Therapeutics, Inc. Class A Common Stock from 2023 to 2023. This chart tracks Contineum Therapeutics, Inc. Class A Common Stock's Capital Reinvestment Ratio across 1 annual periods. Also explore how fast is Contineum Therapeutics, Inc. Class A Com growing its equity to track the company's year-over-year net asset growth rate.
Contineum Therapeutics, Inc. Class A Common Stock Capital Reinvestment Ratio by Year (2023–2023)
Contineum Therapeutics, Inc. Class A Common Stock capital reinvestment ratio by year from 2023 to 2023. For the full cash flow conversion analysis, see cash flow conversion of Contineum Therapeutics, Inc. Class A Com.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.02x | $19.35 Million | $414.00K | — |